Institut De Cancerologie De Lorraine
- Address
- lock Available on a paid plan
Institut De Cancerologie De Lorraine - Comprehensive Cancer Research Center
The Institut De Cancerologie De Lorraine is a leading cancer research institution conducting innovative clinical trials across multiple malignancies. The center demonstrates particular expertise in immuno-oncology and precision medicine, investigating novel therapeutic combinations and biomarker-driven treatment strategies. Their research portfolio spans early-phase through pivotal Phase III trials, emphasizing both treatment optimization and quality of life outcomes for cancer patients.
- Advanced solid tumors including head and neck squamous cell carcinoma, with focus on immunotherapy combinations (avelumab, pembrolizumab, nivolumab) and radiation therapy
- Genitourinary cancers: comprehensive prostate cancer programs (castration-resistant and castration-sensitive disease), renal cell carcinoma (clear cell and non-clear cell), and urothelial carcinoma trials
- Breast cancer research emphasizing HER2-targeted therapies, hormone receptor-positive disease, and triple-negative breast cancer with novel targeted agents
- Gastrointestinal malignancies including colorectal, pancreatic, esophageal, and gastric cancers with focus on chemotherapy optimization and immunotherapy integration
The institute maintains active research programs in rare cancers including sarcomas, penile carcinoma, and pediatric brain tumors (diffuse intrinsic pontine glioma). Their trials frequently incorporate advanced imaging techniques such as PSMA PET/CT and FDG-PET for treatment selection and response assessment. The center's commitment to translational research is evident through numerous studies evaluating biomarkers, circulating tumor markers, and molecular profiling to guide personalized treatment strategies, including BRCA mutation testing and ESR1 mutation analysis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 233 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 203 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut De Cancerologie De Lorraine
lock Showing 1 of 185 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| "CUPCAKE": Early detection of triple negative breast cancer relapse: a clinical utility trial | Institut Curie | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 233 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 31 | Unknown | 2015-07-16 | 2026-05-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.